CA2465420A1 - Anhydrous crystal form of valaciclovir hydrochloride - Google Patents

Anhydrous crystal form of valaciclovir hydrochloride Download PDF

Info

Publication number
CA2465420A1
CA2465420A1 CA002465420A CA2465420A CA2465420A1 CA 2465420 A1 CA2465420 A1 CA 2465420A1 CA 002465420 A CA002465420 A CA 002465420A CA 2465420 A CA2465420 A CA 2465420A CA 2465420 A1 CA2465420 A1 CA 2465420A1
Authority
CA
Canada
Prior art keywords
valaciclovir hydrochloride
anhydrous crystalline
hydrochloride
hydrated
anhydrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002465420A
Other languages
English (en)
French (fr)
Inventor
Helene S Fain
David Alan Jones
Philip G. Lake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2465420A1 publication Critical patent/CA2465420A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002465420A 2001-11-05 2002-10-23 Anhydrous crystal form of valaciclovir hydrochloride Abandoned CA2465420A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33331301P 2001-11-05 2001-11-05
US60/333,313 2001-11-05
PCT/US2002/033926 WO2003040145A1 (en) 2001-11-05 2002-10-23 Anhydrous crystal form of valaciclovir hydrochloride

Publications (1)

Publication Number Publication Date
CA2465420A1 true CA2465420A1 (en) 2003-05-15

Family

ID=23302261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002465420A Abandoned CA2465420A1 (en) 2001-11-05 2002-10-23 Anhydrous crystal form of valaciclovir hydrochloride

Country Status (10)

Country Link
US (2) US20040197396A1 (enExample)
EP (1) EP1453834A1 (enExample)
JP (1) JP2005511612A (enExample)
AU (1) AU2002348022B2 (enExample)
CA (1) CA2465420A1 (enExample)
FR (1) FR2831885A1 (enExample)
GB (1) GB2383038B (enExample)
GR (1) GR1004358B (enExample)
IT (1) ITRM20020555A1 (enExample)
WO (1) WO2003040145A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5043286B2 (ja) * 2001-09-07 2012-10-10 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビル塩酸塩の結晶型
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2465928C (en) * 2001-11-14 2010-01-19 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1638972A2 (en) * 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
CN1331471C (zh) * 2003-09-22 2007-08-15 陈云芳 盐酸万乃洛韦软胶囊组合物
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
CN105753868B (zh) * 2016-04-12 2017-08-01 浙江理工大学 一种盐酸伐昔洛韦的半水合物及其制备方法
CN112176011B (zh) * 2020-10-26 2022-10-18 辰欣药业股份有限公司 一种酶催化制备盐酸伐昔洛韦的方法
CN116754538B (zh) * 2023-06-15 2024-05-07 深圳市新阳唯康科技有限公司 一种阿昔洛韦软膏的晶型定量方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
JP5043286B2 (ja) * 2001-09-07 2012-10-10 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビル塩酸塩の結晶型
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2465928C (en) * 2001-11-14 2010-01-19 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
AU2003277433A1 (en) * 2002-10-16 2004-05-04 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1575953A1 (en) * 2002-12-09 2005-09-21 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP1638972A2 (en) * 2003-06-02 2006-03-29 Teva Pharmaceutical Industries Limited Novel crystalline forms of valacyclovir hydrochloride
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Also Published As

Publication number Publication date
AU2002348022B2 (en) 2006-06-15
GB2383038B (en) 2005-01-19
GB0225771D0 (en) 2002-12-11
ITRM20020555A1 (it) 2003-05-06
GB2383038A (en) 2003-06-18
GR1004358B (el) 2003-10-07
GR20020100478A (el) 2003-07-16
EP1453834A1 (en) 2004-09-08
JP2005511612A (ja) 2005-04-28
US20040197396A1 (en) 2004-10-07
WO2003040145A1 (en) 2003-05-15
US20070093511A1 (en) 2007-04-26
FR2831885A1 (fr) 2003-05-09
ITRM20020555A0 (it) 2002-11-05

Similar Documents

Publication Publication Date Title
AU2002348022B2 (en) Anhydrous crystal form of valaciclovir hydrochloride
AU2002348022A1 (en) Anhydrous crystal form of valaciclovir hydrochloride
JP2024123037A (ja) ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態
AU2020220512B2 (en) FGFR inhibitor compound in solid form and preparation method therefor
MX2010014060A (es) Proceso para preparar un agonista de receptor de adenosina a2a y sus polimorfas.
MXPA06002761A (es) Forma cristalina de sal de calcio de bis [(e)-7-[4 -(4-fluorofenil)- 6-isopropil- 2-[metil(metilsulfonil) amino] pirimidin -5-il](3r, 5s)-3, 5-dihidroxihept -6-acido enoico].
WO2004091619A1 (en) A crystalline form iii of anhydrous moxifloxacin hydrochloride and a process for preparation thereof
JP2021063111A (ja) 二メシル酸パルボシクリブの固体形態
JP2022536489A (ja) ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶性塩形態
EP3322709B1 (en) Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof
CA2479549C (en) Novel crystal form of 5-hydroxy-1-methylhydantoin
WO2017032349A1 (en) Salts of 5-fluoro-3-phenyl-2-[(1s)-1-(9h-purin-6-ylamino)propyl]quinazolin-4-one and preparation thereof
JP7434273B2 (ja) アゼチジン誘導体のボレート
US20090076270A1 (en) Drying process for preparing crystalline solid famciclovir
EP2459520A1 (en) Crystalline forms of fesoterodine fumarate and fesoterodine base
JP2025128032A (ja) ダプロデュスタットの共結晶
CN109516976B (zh) 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法
WO2004089952A1 (en) Novel crystalline forms of abacavir sulfate
EP4608832A1 (en) 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1-yl)acetamide salt and crystalline forms thereof
WO2025215126A1 (en) Synthesis of vidofludimus and its calcium salt
KR20070014164A (ko) 5,11-디하이드로-11-에틸-5-메틸-8-｛2-｛(1-옥시도-4-퀴놀리닐)옥시｝에틸｝-6Ｈ-디피리도［3,2-ｂ：2',3'-ｅ]［1,4］디아제핀-6-온의 결정 형태
EP1861404A1 (en) Polymorphic form of 6- (4-chlorophenyl) -2, 2-dimethyl-7-phenyl-2, 3-dihydro-lh-pyrrolizin-5-ylacetic acid

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued